Here, we first report that the PI3K‐Akt‐β‐catenin signalling pathway, as a target of MARCH1, may help us to better understand how MARCH1 drives tumour development and progression and may help pave the way for the design of novel therapeutic protocols in human HCC treatment. Here, AKT1 is linked to neoplasm.